Indeed, the combination of CDK4/6 and MEK inhibitors has shown remarkable promise in pre-clinical and clinical studies of Ras-driven cancers, such as non-small cell lung cancer (NSCLC) and pancreatic adenocarcinomas [34–36]. This evidence concerns the gene MAP2K7 and non-small cell lung carcinoma.